Evidence map›Paper›PMID 40750876›Full record

ArticleBMC cancer2025

Comparative survival analysis of HER2-positive Pregnancy-Associated Breast Cancer (PABC) and non-Pregnancy-Associated breast Cancer (non-PABC) cohorts: a matched control study.

Mahmoud Al-Masri, Basim Aljalabneh, Rama AlMasri, Osama Alayyan, Mohammad Almasri, Yasmin Safi

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mahmoud Al-MasriDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan. malmasri@khcc.jo.
Basim AljalabnehDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan.
Rama AlMasriDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan.
Osama AlayyanDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan.
Mohammad AlmasriDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan.
Yasmin SafiDepartment of Surgery, King Hussein Cancer Center, P.O. Box 1269, Queen Rania Al Abdullah Street, Al-Jubeiha, Amman, 11941, Jordan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis retrospective matched cohort study aimed to compare survival outcomes between HER2-positive pregnancy-associated breast cancer (PABC) patients and non-PABC patients in Jordan.

methodsA total of 126 HER2-positive patients (63 PABC, 63 matched non-PABC) were analyzed using data from a single tertiary cancer center between April 2006 and January 2021. Matching criteria included age, histopathology, and clinical stage. Outcomes assessed were overall survival (OS) and recurrence-free survival (RFS). Additional analyses examined treatment timing and completion. Survival was evaluated using Kaplan-Meier estimates and log-rank tests.

resultsOverall survival did not differ significantly between PABC and non-PABC groups (p = 0.12), although a clinically meaningful trend toward lower 5-year OS in the PABC group was observed (68% vs. 83%, p = 0.051). RFS was significantly worse in the PABC cohort (p = 0.026), particularly among postpartum breast cancer (PPBC) patients. PABC patients experienced notable delays in initiating anti-HER2 therapy compared to non-PABC patients (mean 21.3 weeks vs. 16.9 weeks, p = 0.02). Completion of anti-HER2 therapy strongly correlated with improved OS and RFS compared to incomplete or no treatment (p = 0.004 and p = 0.02, respectively).

conclusionTimely initiation and completion of anti-HER2 therapy are essential to optimize outcomes in HER2-positive PABC patients. Despite treatment delays, overall survival was maintained when therapy was completed, highlighting the importance of sustained access to multidisciplinary care during and after pregnancy.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesPregnancy Complications, NeoplasticAdultCase-Control StudiesFemaleHumansJordanKaplan-Meier EstimateMiddle AgedPregnancyRetrospective StudiesSurvival AnalysisERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerHER2-Positive breast CancerOncological outcomesPregnancy and CancerPregnancy-Associated breast CancerSurvival analysis

Identifiers

PMID40750876
PMCPMC12315283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.